A Prospective Study of Diffusion-weighted Magnetic Resonance Imaging as an Early Prognostic Biomarker in Chemoradiotherapy in Squamous Cell Carcinomas of the Anus.
Journal article
Muirhead R. et al, (2020), Clin Oncol (R Coll Radiol), 32, 874 - 883
Oxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinoma.
Journal article
Bluemke E. et al, (2020), Clin Transl Radiat Oncol, 22, 44 - 49
A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol.
Journal article
Brown NF. et al, (2020), BMC Cancer, 20
Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer.
Journal article
Robinson M. et al, (2020), Radiother Oncol, 143, 19 - 23
A prospective study of diffusion-weighted magnetic resonance imaging for predicting outcome following chemoradiotherapy, in squamous cell carcinomas of the anus
Conference paper
Muirhead R. et al, (2019)
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
Journal article
McGowan DR. et al, (2019), Eur J Cancer, 113, 87 - 95
Is There a Role for an 18F-fluorodeoxyglucose-derived Biological Boost in Squamous Cell Anal Cancer?
Journal article
Sabbagh A. et al, (2019), Clin Oncol (R Coll Radiol), 31, 72 - 80
Is there a role for a biological boost in squamous cell anal cancer?
Conference paper
Muirhead R. et al, (2018)
Changes in Pelvic Active Bone Marrow seen on FDG-PET in Patients Receiving Concurrent Chemoradiation for Anal Cancer
Conference paper
Robinson M. et al, (2018)
Safety and tumour hypoxia modifying effect of buparlisib with radiotherapy in NSCLC: a phase I dose escalation study
Conference paper
McGowan DR. et al, (2018)